Trial Profile
A second phase III trial to investigate the efficacy of lasofoxifene for the treatment of vulvovaginal atrophy in postmenopausal women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2016
Price :
$35
*
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Atrophic vaginitis
- Focus Therapeutic Use
- Acronyms GARNET
- 10 Feb 2016 Results from this trial will be presented at the annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), according to a Sermonix Pharmaceuticals media release.
- 05 Feb 2016 New trial record